Long term drug delivery devices with polyurethane-based polymers and their manufacture
View Patent ↗This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.
1. An implantable drug delivery device, comprising a polyurethane-based polymer having polyether-based polyol segments represented by the formula O—(CH 2 —CH 2 —CH 2 —CH 2 ) x —O— whereby an increase in “x” represents a decrease in Flex Modulus, said polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of solid formulation comprising an active agent and one or more pharmaceutically acceptable carriers, such that the release of the active agent at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases with the selection of the polyurethane-based polymers of decreasing Flex Modulus, wherein the active agent is risperidone, dexamethasone, naltrexone, metolazone, clonidine, or selegiline.
2. The drug delivery device of claim 1 , wherein the active agent is risperidone.
3. The drug delivery device of claim 1 , wherein the active agent is dexamethasone.
4. The drug delivery device of claim 1 , wherein the active agent is naltrexone.
5. The drug delivery device of claim 1 , wherein the active agent is metolazone.
6. The drug delivery device of claim 1 , wherein the active agent is clonidine.
7. The drug delivery device of claim 1 , wherein the active agent is selegiline.
8. The drug delivery device of claim 1 , wherein the polyurethane-based polymer has a flex modulus of between about 1000 psi and 92,000 psi.
9. The drug delivery device of claim 1 , wherein the polyurethane-based polymer has a flex modulus of about 1000 psi.
10. The drug delivery device of claim 1 , wherein the one or more pharmaceutically acceptable carriers is selected from the group consisting of croscarmellose, stearic acid, and a combination thereof.
11. The drug delivery device of claim 10 , wherein the one or more pharmaceutically acceptable carriers are croscarmellose and stearic acid.
12. The drug delivery device of claim 11 , wherein the croscarmellose comprises 10% of the solid drug formulation, and stearic acid comprises 2% of the solid drug formulation.
13. The drug delivery device of claim 1 , wherein the reservoir has a wall thickness of 0.2 mm.
14. A method of delivering an active agent to a subject, comprising implanting an implantable device into the subject, wherein the implantable device comprises a polyurethane-based polymer having polyether-based polyol segments represented by the formula O—(CH 2 —CH 2 —CH 2 —CH 2 ) x —O— whereby an increase in “x” represents a decrease in Flex Modulus, said polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of solid formulation comprising an active agent and one or more pharmaceutically acceptable carriers, such that the release of the active agent at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases with the selection of the polyurethane-based polymers of decreasing Flex Modulus, wherein the active agent is risperidone, dexamethasone, naltrexone, metolazone, clonidine, or selegiline.
15. The method of claim 14 , wherein the active agent is risperidone.
16. The method of claim 14 , wherein the active agent is dexamethasone.
17. The method of claim 14 , wherein the active agent is naltrexone.
18. The method of claim 14 , wherein the active agent is metolazone.
19. The method of claim 14 , wherein the active agent is clonidine.
20. The method of claim 14 , wherein the active agent is selegiline.
21. The method of claim 14 , wherein the polyurethane-based polymer has a flex modulus of between about 1000 psi and 92,000 psi.
22. The method of claim 14 , wherein the polyurethane-based polymer has a flex modulus of about 1000 psi.
23. The method of claim 14 , wherein the one or more pharmaceutically acceptable carriers is selected from the group consisting of croscarmellose, stearic acid, and a combination thereof.
24. The method of claim 23 , wherein the one or more pharmaceutically acceptable carriers are croscarmellose and stearic acid.
25. The method of claim 24 , wherein the croscarmellose comprises 10% of the solid drug formulation, and stearic acid comprises 2% of the solid drug formulation.
26. The method of claim 14 , wherein the reservoir has a wall thickness of 0.2 mm.